Iovance Biotherapeutics, Inc.
IOVA
$6.98
$0.467.06%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 25.75% | 5.73% | -5.05% | 3.02% | 11.43% |
| Total Depreciation and Amortization | -10.55% | -4.35% | -1.22% | 28.02% | 25.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -55.44% | -46.14% | -33.25% | 7.33% | 55.49% |
| Change in Net Operating Assets | -0.29% | 82.30% | 80.77% | 15.47% | -20.34% |
| Cash from Operations | 12.93% | 19.02% | 14.33% | 11.14% | 21.95% |
| Capital Expenditure | -60.04% | -161.14% | -205.68% | -175.01% | -71.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -151.21% | 75.30% | 348.20% | 176.11% | 115.87% |
| Cash from Investing | -1,078.60% | 38.95% | 149.26% | 136.49% | 102.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37.36% | -27.33% | -23.71% | -36.63% | -61.52% |
| Repurchase of Common Stock | 52.98% | 59.47% | 45.10% | 38.39% | -112.34% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 43.35% | -26.03% | -23.01% | -36.58% | -63.50% |
| Foreign Exchange rate Adjustments | -133.28% | -7.64% | 311.46% | -116.70% | 220.87% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 77.62% | -34.68% | 179.31% | 96.06% | -57.66% |